Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reissued by equities research analysts at Cann in a research note issued to investors on Tuesday. They currently have a $27.00 price objective on the stock. Cann’s price target would suggest a potential upside of 51.26% from the stock’s current price.
The analysts wrote, “The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook.””
KURA has been the topic of several other reports. BidaskClub upgraded Kura Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, January 24th. Wedbush started coverage on Kura Oncology in a report on Tuesday, December 26th. They set a “buy” rating and a $19.00 price objective on the stock. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a report on Wednesday, March 21st. Citigroup set a $28.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Friday, February 16th. Finally, ValuEngine upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Kura Oncology has an average rating of “Buy” and an average target price of $22.00.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.01). analysts expect that Kura Oncology will post -1.43 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Kura Oncology by 49.1% in the 4th quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock worth $23,331,000 after purchasing an additional 502,296 shares in the last quarter. Nexthera Capital LP boosted its position in shares of Kura Oncology by 72.3% in the 4th quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock worth $6,817,000 after purchasing an additional 187,034 shares in the last quarter. State Street Corp acquired a new stake in shares of Kura Oncology in the 2nd quarter worth $1,394,000. Millennium Management LLC boosted its position in shares of Kura Oncology by 35.7% in the 4th quarter. Millennium Management LLC now owns 303,905 shares of the company’s stock worth $4,650,000 after purchasing an additional 79,989 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Kura Oncology in the 3rd quarter worth $802,000. Institutional investors and hedge funds own 58.56% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.